Comprehensive Income (Loss), Net of Tax, Attributable to Parent of LIFECORE BIOMEDICAL, INC. \DE\ from 28 Aug 2011 to 26 May 2024

Taxonomy & unit
us-gaap: USD
Description
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Summary
LIFECORE BIOMEDICAL, INC. \DE\ quarterly and annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD history and change rate from 28 Aug 2011 to 26 May 2024.
  • LIFECORE BIOMEDICAL, INC. \DE\ Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending 26 May 2024 was $7,083,000, a 82% increase year-over-year.
  • LIFECORE BIOMEDICAL, INC. \DE\ Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending 26 May 2024 was $12,013,000.
  • LIFECORE BIOMEDICAL, INC. \DE\ annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was $12,013,000.
  • LIFECORE BIOMEDICAL, INC. \DE\ annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was $98,977,000, a 15% increase from 2021.
  • LIFECORE BIOMEDICAL, INC. \DE\ annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was $115,943,000, a 276% decline from 2020.
Source SEC data
View on sec.gov
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Change (%)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Change (%)

LIFECORE BIOMEDICAL, INC. \DE\ Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2024 $12,013,000 $7,083,000 +$32,201,000 +82% 26 Feb 2024 26 May 2024 10-K 26 Aug 2024 2024 FY
Q1 2024 $20,188,000 $15,632,000 +$52,139,000 27 Nov 2023 25 Feb 2024 10-Q 09 Aug 2024 2024 Q3
Q4 2023 $72,327,000 $14,218,000 +$26,738,000 28 Aug 2023 26 Nov 2023 10-Q 09 Aug 2024 2024 Q2
Q3 2023 $99,065,000 $10,754,000 -$88,000 -0.82% 29 May 2023 27 Aug 2023 10-Q 09 Aug 2024 2024 Q1
Q2 2023 $98,977,000 $39,284,000 +$15,861,000 +29% 27 Feb 2023 28 May 2023 10-K 26 Aug 2024 2024 FY
Q1 2023 $114,838,000 $36,507,000 -$23,025,000 -171% 28 Nov 2022 26 Feb 2023 10-Q 09 Aug 2024 2024 Q3
Q4 2022 $91,813,000 $12,520,000 +$25,775,000 +67% 29 Aug 2022 27 Nov 2022 10-Q 09 Aug 2024 2024 Q2
Q3 2022 $117,588,000 $10,666,000 -$1,645,000 -18% 30 May 2022 28 Aug 2022 10-Q 09 Aug 2024 2024 Q1
Q2 2022 $115,943,000 $55,145,000 -$54,220,000 -5862% 28 Feb 2022 29 May 2022 10-K 26 Aug 2024 2024 FY
Q1 2022 $61,723,000 $13,482,000 -$6,891,000 -105% 29 Nov 2021 27 Feb 2022 10-K 20 Mar 2024 2023 FY
Q4 2021 $54,832,000 $38,295,000 -$27,073,000 -241% 30 Aug 2021 28 Nov 2021 10-K 20 Mar 2024 2023 FY
Q3 2021 $27,759,000 $9,021,000 +$3,085,000 +25% 31 May 2021 29 Aug 2021 10-K 20 Mar 2024 2023 FY
Q2 2021 $30,844,000 $925,000 +$16,200,000 +95% 01 Mar 2021 30 May 2021 10-K 20 Mar 2024 2023 FY
Q1 2021 $47,044,000 $6,591,000 +$5,338,000 +45% 30 Nov 2020 28 Feb 2021 10-K 20 Mar 2024 2023 FY
Q4 2020 $52,382,000 $11,222,000 -$4,609,000 -70% 31 Aug 2020 29 Nov 2020 10-K 20 Mar 2024 2023 FY
Q3 2020 $47,773,000 $12,106,000 -$6,710,000 -124% 01 Jun 2020 30 Aug 2020 10-K 20 Mar 2024 2023 FY
Q2 2020 $41,063,000 $17,125,000 24 Feb 2020 31 May 2020 10-K/A 16 Mar 2023 2022 FY
Q1 2020 $11,929,000 -$12,401,000 -2627% 25 Nov 2019 23 Feb 2020 10-Q 08 Apr 2021 2021 Q3
Q4 2019 $6,613,000 -$6,105,000 -1202% 26 Aug 2019 24 Nov 2019 10-Q 07 Jan 2021 2021 Q2
Q3 2019 $5,396,000 27 May 2019 25 Aug 2019 10-Q 07 Oct 2020 2021 Q1
Q1 2019 $472,000 26 Nov 2018 24 Feb 2019 10-Q 03 Apr 2020 2020 Q3
Q4 2018 $508,000 27 Aug 2018 25 Nov 2018 10-Q 02 Jan 2020 2020 Q2
Q1 2017 $13,297,000 $3,603,000 +$24,793,000 28 Nov 2016 26 Feb 2017 10-Q 07 Apr 2017 2017 Q3
Q4 2016 $11,496,000 $1,653,000 -$215,000 -12% 29 Aug 2016 27 Nov 2016 10-Q 05 Jan 2017 2017 Q2
Q3 2016 $11,281,000 $3,312,000 +$360,000 +12% 30 May 2016 28 Aug 2016 10-Q 29 Sep 2016 2017 Q1
Q2 2016 $11,641,000 $4,729,000 +$533,000 +13% 01 Mar 2016 29 May 2016 10-K 01 Aug 2016 2016 FY
Q1 2016 $12,174,000 $21,190,000 -$24,962,000 -662% 30 Nov 2015 28 Feb 2016 10-Q 07 Apr 2017 2017 Q3
Q4 2015 $12,788,000 $1,868,000 -$1,355,000 -42% 31 Aug 2015 29 Nov 2015 10-Q 05 Jan 2017 2017 Q2
Q3 2015 $14,143,000 $2,952,000 +$599,000 +25% 01 Jun 2015 30 Aug 2015 10-Q 29 Sep 2016 2017 Q1
Q2 2015 $13,544,000 $4,196,000 -$346,000 -7.6% 02 Mar 2015 31 May 2015 10-K 01 Aug 2016 2016 FY
Q1 2015 $13,890,000 $3,772,000 -$2,628,000 -41% 01 Dec 2014 01 Mar 2015 10-K 01 Aug 2016 2016 FY
Q4 2014 $16,518,000 $3,223,000 -$228,000 -6.6% 01 Sep 2014 30 Nov 2014 10-K 01 Aug 2016 2016 FY
Q3 2014 $16,746,000 $2,353,000 -$2,399,000 -50% 02 Jun 2014 31 Aug 2014 10-Q 01 Oct 2015 2016 Q1
Q2 2014 $19,145,000 $4,542,000 +$23,000 +0.51% 24 Feb 2014 25 May 2014 10-K 01 Aug 2016 2016 FY
Q1 2014 $19,122,000 $6,400,000 +$1,611,000 +34% 25 Nov 2013 23 Feb 2014 10-K 01 Aug 2016 2016 FY
Q4 2013 $17,511,000 $3,451,000 -$5,462,000 -61% 26 Aug 2013 24 Nov 2013 10-K 01 Aug 2016 2016 FY
Q3 2013 $22,973,000 $4,752,000 +$386,000 +8.8% 27 May 2013 25 Aug 2013 10-K 01 Aug 2016 2016 FY
Q2 2013 $22,587,000 $4,519,000 +$1,740,000 +63% 25 Feb 2013 26 May 2013 10-K 31 Jul 2015 2015 FY
Q1 2013 $20,847,000 $4,789,000 +$24,000 +0.5% 26 Nov 2012 24 Feb 2013 10-K 31 Jul 2015 2015 FY
Q4 2012 $20,823,000 $8,913,000 +$5,573,000 +167% 27 Aug 2012 25 Nov 2012 10-K 31 Jul 2015 2015 FY
Q3 2012 $15,250,000 $4,366,000 +$2,554,000 +141% 28 May 2012 26 Aug 2012 10-K 31 Jul 2015 2015 FY
Q2 2012 $12,696,000 $2,779,000 27 Feb 2012 27 May 2012 10-K 01 Aug 2014 2014 FY
Q1 2012 $4,765,000 28 Nov 2011 26 Feb 2012 10-K 01 Aug 2014 2014 FY
Q4 2011 $3,340,000 29 Aug 2011 27 Nov 2011 10-K 01 Aug 2014 2014 FY
Q3 2011 $1,812,000 30 May 2011 28 Aug 2011 10-K 01 Aug 2014 2014 FY

LIFECORE BIOMEDICAL, INC. \DE\ Annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $12,013,000 +$110,990,000 29 May 2023 26 May 2024 10-K 26 Aug 2024 2024 FY
2022 $98,977,000 +$16,966,000 +15% 30 May 2022 28 May 2023 10-K 26 Aug 2024 2024 FY
2021 $115,943,000 -$85,099,000 -276% 31 May 2021 29 May 2022 10-K 26 Aug 2024 2024 FY
2020 $30,844,000 +$10,219,000 +25% 01 Jun 2020 30 May 2021 10-K 20 Mar 2024 2023 FY
2019 $41,063,000 -$40,390,000 -6001% 27 May 2019 31 May 2020 10-K/A 16 Mar 2023 2022 FY
2018 $673,000 -$26,218,000 -103% 28 May 2018 26 May 2019 10-K 29 Jul 2021 2021 FY
2017 $25,545,000 29 May 2017 27 May 2018 10-K 14 Aug 2020 2020 FY
2015 $11,641,000 -$25,185,000 -186% 01 Jun 2015 29 May 2016 10-K 01 Aug 2016 2016 FY
2014 $13,544,000 -$5,601,000 -29% 26 May 2014 31 May 2015 10-K 01 Aug 2016 2016 FY
2013 $19,145,000 -$3,442,000 -15% 27 May 2013 25 May 2014 10-K 01 Aug 2016 2016 FY
2012 $22,587,000 +$9,891,000 +78% 28 May 2012 26 May 2013 10-K 31 Jul 2015 2015 FY
2011 $12,696,000 30 May 2011 27 May 2012 10-K 01 Aug 2014 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.